Answers are grounded in this paper and cite their sources.
Background Short preoperative immune induction could inform future breast-cancer trials, but it must not delay surgery. BreastVAX tested whether a single-dose preoperative regimen could be delivered within the planned surgical window while collecting safety and biological data. Methods BreastVAX (NCT04454528) was a single-centre, open-label, phase 1b/2 window-of-opportunity trial. Adults with operable invasive breast cancer scheduled for upfront surgery received one 200 mg pembrolizumab infusion alone or with one 7 Gy tumour-directed radiotherapy fraction before or after pembrolizumab. The primary phase 1b endpoint was feasibility, defined as completion of assigned preoperative treatment within 21 days without delaying surgery by more than 14 days. Phase 2 had two descriptive interim reviews. Findings In phase 1b, all six enrolled participants met the feasibility criterion. Across both phases, all 30 treated participants completed assigned preoperative therapy and underwent surgery without protocol-defined delay; median follow-up was 634 days (IQR 256-1120). Most adverse events were grade 1-2, with no deaths and no treatment-related grade 3 or higher events; the only grade 3 event was a surgical re-excision unrelated to treatment. Pathological and immune-correlative findings were exploratory and showed treatment-associated immune changes, including a neoepitope-reactive T-cell response in one responder. Interpretation Pembrolizumab, with or without a single subablative tumour-directed radiotherapy fraction, was delivered within the preoperative window without protocol-defined surgical delay. Larger biomarker-informed studies should evaluate sequence prospectively, use endpoints suited to this short regimen, and prespecify harms monitoring.
No takes yet. Share an insight, caveat, or question.
Tchou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: